FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212111143> ?p ?o ?g. }

• W3212111143 endingPage "6565" @default.
• W3212111143 startingPage "6557" @default.
• W3212111143 abstract "Relapsed/refractory AML cases are much more resistant to chemotherapy. Venetoclax is a highly sensitive BCL-2 inhibitor. It was aimed to evaluate the effects of venetoclax therapy on real-world R/R AML survival outcomes, the effects of the cytogenetic characteristics of the patients and previous clinical applications on treatment response, and venetoclax treatment toxicity.The study included patients who only received a venetoclax-based salvage on R/R AML patients from Turkey. The study included a total of 62 patients from 6 different centers in Turkey. Response to 2 cycles of venetoclax treatment was assessed by bone marrow blast rate. The demographic data, cytogenetic characteristics, AML type, MDS type, response rates and overall survival of the patients after venetoclax combination treatment were assessed. Median age of the patients was 65 (19-85). Mean number of prior treatments was 2.67 ±1.75.13 patients (21%) had a history of allogenic stem cell transplantation. 58 (93.5%) had received HMA therapy before venetoclax. 36 patients (58.1%) had de-novo AML, and 25 (40.3%) previously had MDS. Treatment response was evaluated as complete remission (n = 21, 33.9%), partial response (n = 17, 27.4%), and treatment failure (n = 24, 38.7%). Patients in the TF group were significantly more likely to have poor cytogenetic and to have received allogeneic transplants. The mean estimated overall survival after the venetoclax treatment was 9.13 ± 0.75 months.The study population consisted of a group of patients who had relapsed or primary refractory disease with poor prognosis, despite numerous rounds of chemotherapy. It is our belief that the high response rates obtained with the combination of venetoclax/HMA, and having obtained positive results with poor risk patients, indicated a promising perspective for R/R AML patients." @default.
• W3212111143 created "2021-11-22" @default.
• W3212111143 creator A5002607533 @default.
• W3212111143 creator A5011557278 @default.
• W3212111143 creator A5018463325 @default.
• W3212111143 creator A5018508176 @default.
• W3212111143 creator A5024389050 @default.
• W3212111143 creator A5025223186 @default.
• W3212111143 creator A5031540444 @default.
• W3212111143 creator A5037716962 @default.
• W3212111143 creator A5049731422 @default.
• W3212111143 creator A5051569347 @default.
• W3212111143 creator A5054644688 @default.
• W3212111143 creator A5055448778 @default.
• W3212111143 creator A5057286844 @default.
• W3212111143 creator A5060842017 @default.
• W3212111143 creator A5072344712 @default.
• W3212111143 creator A5073933491 @default.
• W3212111143 creator A5084146087 @default.
• W3212111143 creator A5084320276 @default.
• W3212111143 creator A5085498128 @default.
• W3212111143 creator A5089024180 @default.
• W3212111143 date "2021-11-01" @default.
• W3212111143 modified "2023-10-01" @default.
• W3212111143 title "Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML." @default.
• W3212111143 doi "https://doi.org/10.26355/eurrev_202111_27126" @default.
• W3212111143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34787859" @default.
• W3212111143 hasPublicationYear "2021" @default.
• W3212111143 type Work @default.
• W3212111143 sameAs 3212111143 @default.
• W3212111143 citedByCount "1" @default.
• W3212111143 countsByYear W32121111432023 @default.
• W3212111143 crossrefType "journal-article" @default.
• W3212111143 hasAuthorship W3212111143A5002607533 @default.
• W3212111143 hasAuthorship W3212111143A5011557278 @default.
• W3212111143 hasAuthorship W3212111143A5018463325 @default.
• W3212111143 hasAuthorship W3212111143A5018508176 @default.
• W3212111143 hasAuthorship W3212111143A5024389050 @default.
• W3212111143 hasAuthorship W3212111143A5025223186 @default.
• W3212111143 hasAuthorship W3212111143A5031540444 @default.
• W3212111143 hasAuthorship W3212111143A5037716962 @default.
• W3212111143 hasAuthorship W3212111143A5049731422 @default.
• W3212111143 hasAuthorship W3212111143A5051569347 @default.
• W3212111143 hasAuthorship W3212111143A5054644688 @default.
• W3212111143 hasAuthorship W3212111143A5055448778 @default.
• W3212111143 hasAuthorship W3212111143A5057286844 @default.
• W3212111143 hasAuthorship W3212111143A5060842017 @default.
• W3212111143 hasAuthorship W3212111143A5072344712 @default.
• W3212111143 hasAuthorship W3212111143A5073933491 @default.
• W3212111143 hasAuthorship W3212111143A5084146087 @default.
• W3212111143 hasAuthorship W3212111143A5084320276 @default.
• W3212111143 hasAuthorship W3212111143A5085498128 @default.
• W3212111143 hasAuthorship W3212111143A5089024180 @default.
• W3212111143 hasConcept C104317684 @default.
• W3212111143 hasConcept C126322002 @default.
• W3212111143 hasConcept C142424586 @default.
• W3212111143 hasConcept C143998085 @default.
• W3212111143 hasConcept C150194340 @default.
• W3212111143 hasConcept C190727270 @default.
• W3212111143 hasConcept C2776012956 @default.
• W3212111143 hasConcept C2776694085 @default.
• W3212111143 hasConcept C2777938653 @default.
• W3212111143 hasConcept C2778461978 @default.
• W3212111143 hasConcept C2779675984 @default.
• W3212111143 hasConcept C2780775027 @default.
• W3212111143 hasConcept C2908647359 @default.
• W3212111143 hasConcept C2911091166 @default.
• W3212111143 hasConcept C55493867 @default.
• W3212111143 hasConcept C71924100 @default.
• W3212111143 hasConcept C86803240 @default.
• W3212111143 hasConcept C87355193 @default.
• W3212111143 hasConcept C90924648 @default.
• W3212111143 hasConcept C99454951 @default.
• W3212111143 hasConceptScore W3212111143C104317684 @default.
• W3212111143 hasConceptScore W3212111143C126322002 @default.
• W3212111143 hasConceptScore W3212111143C142424586 @default.
• W3212111143 hasConceptScore W3212111143C143998085 @default.
• W3212111143 hasConceptScore W3212111143C150194340 @default.
• W3212111143 hasConceptScore W3212111143C190727270 @default.
• W3212111143 hasConceptScore W3212111143C2776012956 @default.
• W3212111143 hasConceptScore W3212111143C2776694085 @default.
• W3212111143 hasConceptScore W3212111143C2777938653 @default.
• W3212111143 hasConceptScore W3212111143C2778461978 @default.
• W3212111143 hasConceptScore W3212111143C2779675984 @default.
• W3212111143 hasConceptScore W3212111143C2780775027 @default.
• W3212111143 hasConceptScore W3212111143C2908647359 @default.
• W3212111143 hasConceptScore W3212111143C2911091166 @default.
• W3212111143 hasConceptScore W3212111143C55493867 @default.
• W3212111143 hasConceptScore W3212111143C71924100 @default.
• W3212111143 hasConceptScore W3212111143C86803240 @default.
• W3212111143 hasConceptScore W3212111143C87355193 @default.
• W3212111143 hasConceptScore W3212111143C90924648 @default.
• W3212111143 hasConceptScore W3212111143C99454951 @default.
• W3212111143 hasIssue "21" @default.
• W3212111143 hasLocation W32121111431 @default.
• W3212111143 hasOpenAccess W3212111143 @default.
• W3212111143 hasPrimaryLocation W32121111431 @default.
• W3212111143 hasRelatedWork W10198250 @default.

• next